GCC ATTR-CM burden estimates range from 15,000-25,000 down to a narrower 2,000-5,000, but fewer than 1,000 patients are confirmed diagnosed under either definition.
AXLRx's own GCC ATTR amyloidosis research base carries two burden estimates that do not immediately reconcile, and a funnel model has to hold both rather than pick one. The broader estimate, drawn from HFpEF-adjacent population modeling, places GCC ATTR-CM burden at 15,000-25,000 patients, against fewer than 1,000 diagnosed, an under-5% diagnosis rate. A narrower estimate, built from active launch-readiness tracking of the wild-type, age-related sub-population specifically (ATTRwt-CM in males 65+ with HFpEF, the population without the GCC's rare hereditary variants), places that cohort at 2,000-5,000 patients, of whom fewer than 300-400 are currently diagnosed. The gap between the two is definitional scope, not disagreement: the broader figure captures the full HFpEF-adjacent population plausibly carrying ATTR-CM before any diagnostic filter, while the narrower figure tracks the near-term addressable cohort a launch team can actually plan against.
Whichever definition a commercial team adopts, the conversion bottleneck is identical. Tc-PYP scintigraphy, the non-invasive diagnostic standard for ATTR-CM, is available at fewer than 8 centres across all six GCC states (KFSH&RC, AUH, KAMC, HMC Doha, OCCI Muscat), and most regional HFpEF patients are managed by general cardiologists without ATTR-specific workup. That single constraint explains why both the broader and narrower burden estimates convert to a similarly small confirmed-diagnosis count: fewer than 1,000 under the broad definition, fewer than 300-400 under the narrow one. A GCC-specific hereditary ATTRv population, an estimated 500-1,000 patients carrying Arabian Peninsula variants such as Ala97Ser, Glu89Gln, and Thr60Ala, sits alongside both estimates and faces the same scintigraphy and genetic-testing access gap.
GCC ATTR amyloidosis funnel — reconciling two burden estimates against a shared diagnostic constraint
| Funnel Stage | Population | Source |
|---|---|---|
| Broader ATTR-CM burden estimate (HFpEF-adjacent) | 15,000-25,000 | AXLRx ATTR disease-landscape research base (GCC) |
| Diagnosed under broad definition | Fewer than 1,000 (under 5%) | AXLRx ATTR disease-landscape research base (GCC) |
| Narrower, actively-tracked ATTRwt-CM cohort | 2,000-5,000 | AXLRx ATTR launch-readiness research base (GCC) |
| Diagnosed under narrow definition | Fewer than 300-400 | AXLRx ATTR launch-readiness research base (GCC) |
| GCC centres offering Tc-PYP scintigraphy (shared constraint) | Fewer than 8 | AXLRx ATTR disease-landscape and launch-readiness research base (GCC) |
| ATTRv (hereditary) patients, Arabian Peninsula variants | 500-1,000 | AXLRx ATTR disease-landscape research base (GCC) |
Sources: AXLRx ATTR amyloidosis disease-landscape, competitive-intelligence, payer-HTA, and launch-readiness research base (GCC), synthesized for this funnel.
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- The definitional-scope reconciliation: broad HFpEF-adjacent estimate vs narrow actively-tracked cohort
- Why both numbers are presented side by side rather than resolved into one
Delivers
- The Tc-PYP scintigraphy access constraint (fewer than 8 centres region-wide) as the shared bottleneck
- Why diagnostic capacity, not drug registration, sets the addressable pool
Delivers
- 8-sheet structure (Strategic Context, Inputs, Model, Projections, Sensitivity, References, Market Context, QC)
- Live formulas, zero hardcoded cells; source citation per conversion step across both burden-estimate scenarios
Custom model delivered in 72 hours.
Commission This ModelWhat's inside
- Why Tc-PYP scintigraphy access, not drug registration or price, sets the addressable pool
- Reconciling the two GCC burden estimates before the rest of the model is built out
- Broader estimate: 15,000-25,000 HFpEF-adjacent ATTR-CM burden
- Narrower estimate: 2,000-5,000 actively-tracked ATTRwt-CM cohort
- Fewer than 1,000 diagnosed under the broad definition (under 5% diagnosis rate)
- Fewer than 300-400 diagnosed under the narrow, actively-tracked definition
- 500-1,000 estimated GCC ATTRv patients (Ala97Ser, Glu89Gln, Thr60Ala variants)
- Why ATTRwt-CM in males 65+ is the commercial-target population
- SFDA/MOH registration status by drug and its relevance versus diagnostic capacity
- Fewer than 8 GCC centres offering Tc-PYP scintigraphy, the true gating constraint
- Which assumption, burden definition or scintigraphy capacity, moves the eligible pool most
- Scenario ranges across both burden estimates
- Patient volume by horizon under conservative, base, and aggressive scenarios, modeled against both burden estimates
- Revenue translation inputs
- The open questions your forecasting team must close before the model is finalised
- Structured for an internal forecast-review session
Included with every brief
How AXLRx builds this model
Prepared by MoatRx analysts.
Every AXLRx patient flow model is built on a five-layer funnel: population, disease burden (E1), diagnosis and specialist capture (E2), treatment and biomarker eligibility (E3), market access (E4), then Year 1-3-5 projections across three scenarios. Delivered as a live Excel workbook, not a static table, across 8 sheets with zero hardcoded cells.
GCC ATTR amyloidosis sources: AXLRx's own disease-landscape, competitive-intelligence, payer-HTA, and launch-readiness research base for the GCC market, presenting both the broader HFpEF-adjacent burden estimate and the narrower actively-tracked ATTRwt-CM cohort as a deliberate triangulation rather than a single resolved figure.
- Broader GCC ATTR-CM burden estimate (15,000-25,000) and diagnosis rate verified against the AXLRx GCC disease-landscape research base
- Narrower GCC ATTRwt-CM cohort estimate (2,000-5,000) and diagnosed count verified against the AXLRx GCC launch-readiness research base
- Tc-PYP scintigraphy centre count (fewer than 8 region-wide) verified against both the AXLRx GCC disease-landscape and launch-readiness research bases
- GCC ATTRv hereditary variant population verified against the AXLRx GCC disease-landscape research base
Frequently asked questions
Commission this model
AXLRx delivers rare-disease patient flow models built for forecasting and launch teams sizing the GCC ATTR amyloidosis opportunity, reconciling multiple burden estimates against real diagnostic-capacity constraints. Custom model in 72 hours.
Specify your indication, market, and cohort definition.
AXLRx analyst confirms funnel scope and comparator set before building.
Research-verified patient flow model in 72 hours with optional analyst readout.